查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1848695

免疫腫瘤臨床試驗市場（依治療類型、臨床試驗階段、適應症、申辦者類型、臨床試驗類型及病人入組分類）－2025-2032年全球預測

Immuno-oncology Clinical Trials Market by Therapy Type, Trial Phase, Indication, Sponsor Type, Trial Type, Patient Enrollment - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，免疫腫瘤臨床試驗市場規模將達到 164.7 億美元，複合年成長率為 12.14%。

關鍵市場統計數據
基準年 2024 65.8億美元
預計年份：2025年 74億美元
預測年份 2032 164.7億美元
複合年成長率 (%) 12.14%

本文簡要概述了不斷發展的免疫腫瘤學臨床試驗格局，重點關注轉化成熟度、相關人員合作以及推進試驗進展的必要操作。

在生物學知識融合、先進製造平台和日益精細的試驗設計的推動下，免疫腫瘤學臨床試驗領域已進入加速創新階段。過去十年，免疫調節療法已從早期概念驗證試驗發展為複雜的多臂、生物標記增強型試驗，並將轉化終點與臨床療效相結合。這一趨勢反映了該領域的成熟，機制理解、患者選擇、聯合治療策略以及基礎治療方法共同決定了該計畫的可行性。

轉化科學如今更有力地支持臨床試驗假設，伴隨診斷和詳細的免疫監測已被納入試驗方案，從而實現適應性決策。同時，申辦方需要在細胞和基因治療方法的物流和監管要求與加速臨床試驗進程和擴大生產規模的需求之間尋求平衡。因此，學術中心、生物技術公司和大型製藥企業之間的跨領域合作日益增多，促成了臨床試驗網路和聯盟的形成，旨在共用專業知識、標準化檢測方法並加快罕見疾病適應症的患者招募。

因此，決策者必須整合生物學原理、操作可行性和監管途徑，對資產和研究設計進行優先排序。圍繞著患者細分、終點選擇和生產穩定性等方面的策略清晰度，將是專案從早期階段的潛力轉化為持續臨床影響的關鍵。

科學融合、製造創新和監管適應性如何重塑免疫腫瘤學的臨床試驗策略和治療路徑

在科學突破、技術進步和不斷變化的監管預期推動下，腫瘤免疫學領域正經歷著變革性的轉變。從機制上看，該領域正從單一藥物的查核點阻斷療法轉向整合療法，將過繼性細胞療法、疫苗、細胞激素調節和靶向溶瘤藥物相結合，以克服抗藥性並擴大有效人群。這項轉變的基礎是對腫瘤微環境異質性、克隆動力學和免疫逃脫機制的深入理解，這些理解共同促成了合理的聯合治療策略和更精準的患者選擇。

技術進步也改變了外科手術的現況。細胞製造、冷凍保存和分散式生產方法的改進正在縮短複雜臨床試驗的前置作業時間，並擴大其地理覆蓋範圍。同時，用於遠端監測、分散式研究中心責任制和真實世界數據整合的數位健康工具正在提高臨床試驗的靈活性和患者留存率。在監管方面，我們看到一些漸進式的調整，包括適應症導向設計、籃式試驗和傘式試驗，以及基於可靠替代終點的有條件核准框架。

在金融方面，投資重心正轉向後期、低風險的資產和平台技術，這些資產和技術能夠衍生出多個臨床項目。因此，策略夥伴關係和平台授權變得越來越普遍，這使得規模較小的創新者能夠獲得開發能力，同時也使規模較大的贊助商能夠實現產品線的多元化。累積，這將形成一個更複雜、協作和高效的生態系統，在這個系統中，科學創新和營運創新共同演進，從而拓展治療潛力。

評估計劃於2025年實施的美國關稅對臨床試驗物流、生產製造和跨境合作的營運和戰略影響。

美國2025年定向關稅政策的實施，為依賴全球採購的原料、專用設備和跨境臨床合作進行免疫腫瘤學試驗的申辦者帶來了重要的營運考量。實驗室試劑、輔助器具和某些生物製藥的進口關稅提高，正在逐步增加複雜臨床試驗（尤其是依賴海外生產的試劑和一次性耗材的過繼性細胞療法）的每位患者的成本結構。除了直接的成本影響外，關稅還會影響採購計畫和庫存策略，因為申辦者和臨床試驗中心會採取更保守的供應鏈緩衝措施來降低中斷風險。

為此，許多公司正在加速關鍵製造流程的在地化，並對國內關鍵原料供應商進行資格認證，以降低進口波動帶來的風險。這種轉變也影響資本配置，申辦方紛紛投資於本土受託製造廠商，擴大內部製程開發能力，並重新談判供應商合約以納入緊急條款。因此，臨床試驗預算和臨床實驗選擇標準越來越重視臨床可行性和供應鏈韌性的綜合考量。

海關主導動態也影響共同研究模式。國際學術合作和跨國臨床試驗網路在協調物資轉移和跨司法管轄區統一GMP規範方面面臨日益複雜的行政管理挑戰。因此，申辦方優先考慮監管協調、跨境物流預先規劃以及儘早與海關和貿易專家接洽。雖然短期內某些專案的營運成本和時間有所增加，但對供應鏈穩健性的日益重視正在帶來長期效益，例如提高生產冗餘度和品質保證。

綜合細分分析揭示了治療方式、臨床試驗週期、臨床適應症、申辦者概況和入組規模方面的差異，從而提供了策略啟示。

精細化的細分視角能夠提供切實可行的洞察，幫助我們了解治療前景與營運準備和臨床檢驗的契合點。依治療類型分類，我們檢視了過繼性細胞療法、癌症疫苗、查核點抑制劑、細胞激素療法和溶瘤病毒。過繼性細胞療法再細分為CAR-T細胞療法、NK細胞療法和TCR-T細胞療法。癌症疫苗包括樹突細胞疫苗、DNA疫苗和胜肽疫苗。查核點抑制劑根據其標靶CTLA-4、PD-1和PD-L1進行區分。細胞激素療法以干擾素療法和白細胞介素-2為特徵，而干擾素療法進一步細分為α干擾素和干擾素γ。這種治療分類方法闡明了技術風險和生產複雜性，表明基於平台的細胞療法需要廣泛的供應鏈協調，而肽類疫苗和特定的免疫查核點策略則更容易實現規模化生產。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴展雙特異性抗體平台，透過雙重查核點抑制標靶固態腫瘤微環境
  • 採用個人化新抗原疫苗策略並結合查核點阻斷療法
  • CAR-T細胞療法與免疫查核點抑制劑聯合治療造血系統惡性腫瘤的研發
  • 將基於先進生物標記的患者分層與多組體學相結合，用於預測免疫治療反應
  • 利用CAR構建體進行基因改造，可快速針對腫瘤的現成同種異體自然殺手細胞療法的出現
  • 研究透過調節微生物組來提高癌症免疫療法的療效並降低其毒性的方法

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依治療類型分類的免疫腫瘤臨床試驗市場

  • 過繼性細胞療法
    • CAR-T
    • NK細胞療法
    • Tcr-T
  • 癌症疫苗
    • 樹突細胞疫苗
    • DNA疫苗
    • 胜肽疫苗
  • 查核點抑制劑
    • Ctla-4抑制劑
    • Pd-1抑制劑
    • Pd-L1抑制劑
  • 細胞激素療法
    • 干擾素療法
      • α干擾素
      • 干擾素γ
    • 白細胞介素-2
  • 溶瘤病毒

9. 依試驗階段分類的免疫腫瘤學臨床試驗市場

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第10章 依適應症分類的免疫腫瘤學臨床試驗市場

  • 造血系統惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
  • 固態腫瘤
    • 乳癌
    • 大腸直腸癌
    • 肺癌
    • 黑色素瘤

第11章：以申辦單位類型分類的免疫腫瘤臨床試驗市場

  • 學術機構
  • 生技公司
  • 聯盟
  • 製藥公司

第12章：按試驗類型分類的免疫腫瘤學臨床試驗市場

  • 侵入性的
  • 觀察

13. 依患者入組人數分類的免疫腫瘤臨床試驗市場

  • 大規模
  • 中號
  • 小規模

第14章 各地區的免疫腫瘤臨床試驗市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 免疫腫瘤臨床試驗市場（按組別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：各國免疫腫瘤臨床試驗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    • Roche Holding AG
    • AstraZeneca PLC
    • Novartis AG
    • Pfizer Inc.
    • Johnson & Johnson
    • Amgen Inc.
    • Sanofi SA
    • GlaxoSmithKline plc
Product Code: MRR-035590447475

The Immuno-oncology Clinical Trials Market is projected to grow by USD 16.47 billion at a CAGR of 12.14% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.58 billion
Estimated Year [2025] USD 7.40 billion
Forecast Year [2032] USD 16.47 billion
CAGR (%) 12.14%

A concise synthesis of the evolving immuno-oncology trial environment highlighting translational maturation, multi-stakeholder collaboration, and operational imperatives for advancement

The immuno-oncology clinical trial landscape has entered a phase of accelerated innovation driven by converging biological insights, advanced manufacturing platforms, and increasingly sophisticated trial designs. Over the past decade, immune-modulating modalities have evolved from early proof-of-concept studies to complex, multi-arm, biomarker-enriched trials that integrate translational endpoints alongside clinical efficacy. This trend reflects a maturing field where mechanistic clarity, patient selection, and combination strategies determine program viability as much as the underlying therapeutic modality.

Translational science now underpins trial hypotheses more consistently, with companion diagnostics and deep immune monitoring embedded in protocols to enable adaptive decision-making. At the same time, sponsors are balancing the logistical and regulatory demands of cell- and gene-based interventions with the imperative to reduce time-to-clinic and scale manufacturing. As a result, cross-sector collaboration among academic centers, biotechnology firms, and large pharmaceutical organizations has intensified, with trial networks and consortiums forming to share expertise, standardize assays, and accelerate enrollment for rare indications.

Consequently, decision-makers must synthesize biological rationale, operational feasibility, and regulatory pathways to prioritize assets and trial designs. Strategic clarity around patient segmentation, end-point selection, and manufacturing resilience will be a differentiator for programs that advance beyond early-stage promise to durable clinical impact

How scientific convergence, manufacturing innovation, and regulatory adaptability are reshaping clinical trial strategies and therapeutic pathways in immuno-oncology

The immuno-oncology landscape is undergoing transformative shifts driven by scientific breakthroughs, technology diffusion, and evolving regulatory expectations. Mechanistically, the field is moving beyond single-agent checkpoint blockade toward integrated approaches that combine adoptive cell therapies, vaccines, cytokine modulation, and targeted oncolytics to overcome resistance and broaden responder populations. This transition is supported by enhanced understanding of tumor microenvironment heterogeneity, clonal dynamics, and immune evasion mechanisms, which collectively enable rational combination strategies and more precise patient selection.

Technological advances have also altered operational realities. Improvements in cell manufacturing, cryopreservation, and decentralized production modalities are reducing lead times and expanding the feasible geography for complex trials. Simultaneously, digital health tools for remote monitoring, decentralization of site responsibilities, and real-world data integration are increasing trial flexibility and patient retention. Regulatory pathways are adapting incrementally, with agencies signaling openness to adaptive designs, basket and umbrella studies, and conditional approval frameworks based on robust surrogate endpoints.

Financially, investment focus is shifting toward later-stage de-risked assets and platform technologies that can generate multiple clinical programs. As a result, strategic partnerships and platform licensing are becoming more common, enabling smaller innovators to access development capacity while larger sponsors diversify pipelines. The cumulative effect is a more intricate, collaborative, and efficient ecosystem, where scientific innovation and operational innovation co-evolve to expand therapeutic possibilities

Assessing the operational and strategic ripple effects of United States tariff measures introduced in 2025 on clinical trial logistics, manufacturing, and cross-border collaborations

The introduction of targeted tariff policies in the United States in 2025 has introduced a material operational consideration for sponsors conducting immuno-oncology trials that depend on globally sourced materials, specialized instruments, and cross-border clinical collaborations. Higher import duties on laboratory reagents, ancillary devices, and certain biologic components have incrementally increased the per-patient cost structure for complex trials, particularly for adoptive cell therapies that rely on reagents and single-use consumables often manufactured abroad. Beyond direct cost effects, tariffs influence procurement timelines and inventory strategies as sponsors and clinical sites adopt more conservative supply chain buffers to mitigate disruption risk.

In response, many organizations are accelerating localization of critical manufacturing steps and qualifying domestic suppliers for key inputs to reduce exposure to import fluctuations. This shift has implications for capital allocation, as sponsors invest in onshore contract manufacturing organizations, expand in-house process development capabilities, and renegotiate supplier contracts to include contingency clauses. As a result, trial budgets and site selection criteria are increasingly evaluated through a lens that combines clinical feasibility with supply chain resiliency.

Tariff-driven dynamics also affect collaborative models. International academic partnerships and multi-national trial networks face heightened administrative complexity in coordinating material transfers and aligning GMP specifications across jurisdictions. Consequently, sponsors are prioritizing regulatory harmonization, advanced planning for cross-border logistics, and early engagement with customs and trade specialists. While the near-term impact has been to elevate operational costs and timelines for some programs, the enforced emphasis on supply chain robustness is catalyzing long-term benefits in manufacturing redundancy and quality assurance that will inform program design and go-to-market planning going forward

Integrated segmentation analysis illuminating therapeutic modality distinctions, trial lifecycle differences, clinical indications, sponsor profiles, and enrollment scale implications for strategy

A granular segmentation lens yields actionable insight into where therapeutic promise aligns with operational readiness and clinical validation. Based on therapy type, the landscape encompasses adoptive cell therapies, cancer vaccines, checkpoint inhibitors, cytokine therapies, and oncolytic viruses, with adoptive cell therapies subdivided into CAR-T, NK cell therapy, and TCR-T while cancer vaccines include dendritic cell, DNA, and peptide approaches; checkpoint inhibitors remain differentiated by CTLA-4, PD-1, and PD-L1 targets, and cytokine efforts feature interferon therapies and interleukin-2 where interferon approaches are further specified by interferon alpha and interferon gamma. This therapeutic taxonomy clarifies technological risk and manufacturing complexity, showing that platform-based cell therapies require extensive supply chain coordination, whereas peptide vaccines and certain checkpoint strategies scale more readily.

Based on trial phase, programs span Phase I through Phase IV, with early-phase work dominated by exploratory biomarker integration and safety optimization and later-phase studies emphasizing registrational endpoints and payer-relevant outcomes. Based on indication, the portfolio splits between hematological malignancies and solid tumors; hematologic programs target leukemia, lymphoma, and myeloma while solid tumor efforts focus on breast, colorectal, lung cancers, and melanoma. This dichotomy reveals divergent patient-recruitment strategies and endpoint selection, as hematologic trials frequently rely on measurable disease markers and centralized labs, and solid tumor trials demand robust imaging cohorts and site differentiation.

Based on sponsor type, trials are sponsored by academic institutions, biotechnology companies, consortiums, and pharmaceutical companies, each bringing differing governance, operational scale, and access to patient networks. Based on trial type, the field divides into interventional and observational studies, with interventional designs driving therapeutic validation and observational cohorts generating real-world evidence. Finally, based on patient enrollment, trials range from small-scale, focused cohorts to medium and large-scale studies, a distribution that influences statistical design, site selection, and resource allocation. Together these segmentation lenses inform prioritization by aligning scientific hypotheses with executional capacity and strategic intent

Evaluating geographical strengths and operational trade-offs across the Americas, Europe Middle East & Africa, and Asia-Pacific to optimize trial sequencing and site selection

Regional dynamics continue to shape trial strategy and operational design, as each geography presents unique scientific, regulatory, and logistical attributes that influence program feasibility and speed to evidence. In the Americas, the trial ecosystem benefits from dense networks of academic medical centers, mature regulatory frameworks, and established contract manufacturing capacity, which together support complex cell- and gene-based programs and facilitate rapid cohort accrual for certain indications. Conversely, site selection decisions must account for regional variations in payer expectations and post-approval adoption pathways to ensure that late-stage evidence aligns with commercialization plans.

In Europe, Middle East & Africa, heterogeneity in regulatory processes, reimbursement pathways, and clinical infrastructure necessitates early regulatory engagement and protocol harmonization across countries. This region offers valuable opportunities for multinational enrollment in both rare hematologic indications and diverse solid tumor cohorts, but success depends on centralized data management and consistent assay standardization. Meanwhile, in the Asia-Pacific region, rising clinical research capacity, expanding biotech innovation hubs, and cost-effective manufacturing options present compelling advantages for both early-phase studies and larger, pragmatic trials. However, ethical review timelines, import-export logistics, and local manufacturing qualification must be integrated into program timelines.

Across regions, sponsors are employing hybrid trial models, leveraging decentralized elements where appropriate and aligning site responsibilities with regional strengths. Strategic regional sequencing-initiating proof-of-concept work in centers with deep translational expertise, then scaling into regions with high patient availability and manufacturing support-continues to be a dominant approach for programs aiming to optimize speed, cost, and evidentiary rigor

Examining strategic behaviors of platform-focused innovators, mid-size biotechs, academic consortia, and service partners to identify partnership models and execution strengths

Company behavior within immuno-oncology trials reflects a bifurcation between platform-oriented innovators and indication-focused developers, creating complementary roles in the ecosystem. Large pharmaceutical organizations tend to emphasize late-stage validation, global regulatory strategy, and commercialization readiness, investing heavily in registrational trials and global supply chain infrastructure. Mid-sized biotechnology companies often concentrate on first-in-human proof-of-concept and translational validation, leveraging adaptive designs and biomarker-enriched cohorts to rapidly iterate on mechanism and dose. Meanwhile, academic institutions and consortia provide foundational science, investigator-led trials, and access to specialized assays and patient populations that are critical for early signal generation.

Partnership models are increasingly sophisticated, ranging from co-development and joint governance to licensing arrangements where platform owners supply manufacturing and process expertise while partners drive clinical execution. Contract research organizations and contract manufacturing organizations play essential roles in scaling trials, particularly for cell- and gene-based modalities, where GMP compliance, chain-of-identity controls, and cold-chain logistics are paramount. Observed strategic behaviors include portfolio pruning-where companies prioritize fewer, higher-conviction programs-and platform consolidation, where single technological approaches are extended across multiple indications to capture development leverage.

Taken together, company-level insights suggest that sponsors who align clinical ambition with manufacturing capacity, regulatory strategy, and a clear partnership model tend to execute trials with greater predictability. Executives should therefore assess organizational strengths against the modality-specific demands of their pipeline and consider strategic alliances that mitigate operational risk while accelerating clinical validation

Practical, high-impact steps for executives to align scientific priorities with manufacturing resilience, adaptive trial design, translational rigor, and strategic partnerships

Industry leaders must take deliberate steps to convert scientific opportunity into operationally sound programs that reach patients efficiently and generate durable evidence. First, prioritize portfolio rationalization centered on mechanistic clarity and operational realism; focus resources on assets where biological rationale, manufacturability, and a feasible regulatory pathway align. Second, invest in manufacturing resilience by qualifying multiple suppliers for critical reagents, expanding domestic capacity for sensitive inputs, and embedding contingency planning into contracts and budgets. These measures reduce vulnerability to supply chain shocks and support predictable trial timelines.

Third, adopt flexible trial designs that integrate adaptive elements, biomarker-driven cohorts, and decentralized components where clinically appropriate. This approach accelerates learning, reduces unnecessary exposure, and improves patient access. Fourth, strengthen translational frameworks that couple protocol-design with robust immune monitoring and harmonized assays to generate interpretable mechanistic readouts that inform downstream decisions. Fifth, pursue selective partnerships: collaborate with academic centers for early translational depth, with specialized CMOs for manufacturing scale-up, and with experienced CROs for complex operational execution. Finally, ensure early payer and regulatory engagement to align evidentiary programs with reimbursement expectations and approval pathways, thereby smoothing the path from clinical proof to patient access.

By executing these imperatives in concert, leaders can reduce development risk, compress timelines, and enhance the probability that promising immuno-oncology interventions translate into meaningful clinical and commercial outcomes.

Transparent description of data sources, analytical techniques, expert validation steps, and limitations used to construct actionable insights across clinical, operational, and regulatory dimensions

This report synthesizes evidence from trial registries, peer-reviewed translational studies, regulatory guidance documents, and primary consultations with clinical operations leaders, manufacturing experts, and regulatory affairs practitioners to build a comprehensive view of the immuno-oncology trial landscape. Data integration emphasized trial-level attributes such as modality, phase, indication, sponsor type, trial design features, and site geography, augmented by qualitative input on manufacturing practices, supply chain constraints, and partnership structures. Analytical methods included cross-sectional comparisons to identify operational differentiators, case-based analysis of representative programs to illustrate best practices, and scenario planning to assess the effects of policy shifts and supply chain disruptions.

Quality assurance processes included triangulation across multiple independent sources, validation of protocol-level descriptions against sponsor disclosures, and expert review to ensure clinical and operational plausibility. Where proprietary datasets were used to augment public information, findings were presented at an aggregated level to preserve confidentiality while enabling actionable insight. Limitations of the methodology are acknowledged: rapidly evolving trial outcomes, emerging regulatory guidance, and real-time supply chain changes may alter operational calculus. To mitigate these limitations, recommended usage includes periodic updates and targeted deep dives focused on specific modalities or geographies. The methodological approach supports decision-makers by linking empirical trial attributes with executable operational recommendations and strategic pathways for program advancement

A decisive synthesis highlighting how aligned scientific, manufacturing, and regulatory strategies convert translational promise into sustainable clinical and patient impact

In conclusion, the immuno-oncology clinical trial ecosystem is characterized by a dynamic interplay between scientific innovation, operational sophistication, and strategic collaboration. Therapeutic advances are unlocking new avenues to address both hematologic and solid tumor indications, but successful translation depends on aligning technical complexity with manufacturing capability, regulatory foresight, and patient-centered trial design. Tariff policies and supply chain pressures have elevated the importance of localized manufacturing and robust supplier strategies, while regional strengths shape where programs initiate proof-of-concept work and where they scale to registrational validation.

Decision-makers should act with strategic focus: concentrate on high-conviction assets where translational rationale is supported by operational feasibility, establish partnerships that fill capability gaps, and adopt flexible trial designs that accelerate learning while managing risk. By integrating translational rigor with pragmatic operational planning and regional sequencing, sponsors can increase the probability that promising immuno-oncology approaches progress from experimental validation to meaningful clinical impact. The path forward requires coordinated investment across science, manufacturing, and trial design to ensure that therapeutic innovation reaches patients efficiently and sustainably

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of bispecific antibody platforms targeting solid tumor microenvironments with dual checkpoint inhibition
  • 5.2. Adoption of personalized neoantigen vaccine strategies integrated with checkpoint blockade therapies
  • 5.3. Development of combination regimens involving CAR T cell therapy and immune checkpoint inhibitors in hematologic malignancies
  • 5.4. Integration of advanced biomarker-driven patient stratification using multiomics for immunotherapy response prediction
  • 5.5. Emergence of off-the-shelf allogeneic natural killer cell therapies engineered with CAR constructs for rapid tumor targeting
  • 5.6. Investigation of microbiome modulation approaches to enhance efficacy and reduce toxicities of cancer immunotherapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immuno-oncology Clinical Trials Market, by Therapy Type

  • 8.1. Adoptive Cell Therapies
    • 8.1.1. Car-T
    • 8.1.2. Nk Cell Therapy
    • 8.1.3. Tcr-T
  • 8.2. Cancer Vaccines
    • 8.2.1. Dendritic Cell Vaccines
    • 8.2.2. Dna Vaccines
    • 8.2.3. Peptide Vaccines
  • 8.3. Checkpoint Inhibitors
    • 8.3.1. Ctla-4 Inhibitors
    • 8.3.2. Pd-1 Inhibitors
    • 8.3.3. Pd-L1 Inhibitors
  • 8.4. Cytokine Therapies
    • 8.4.1. Interferon Therapies
      • 8.4.1.1. Interferon Alpha
      • 8.4.1.2. Interferon Gamma
    • 8.4.2. Interleukin-2
  • 8.5. Oncolytic Viruses

9. Immuno-oncology Clinical Trials Market, by Trial Phase

  • 9.1. Phase I
  • 9.2. Phase Ii
  • 9.3. Phase Iii
  • 9.4. Phase Iv

10. Immuno-oncology Clinical Trials Market, by Indication

  • 10.1. Hematological Malignancies
    • 10.1.1. Leukemia
    • 10.1.2. Lymphoma
    • 10.1.3. Myeloma
  • 10.2. Solid Tumors
    • 10.2.1. Breast Cancer
    • 10.2.2. Colorectal Cancer
    • 10.2.3. Lung Cancer
    • 10.2.4. Melanoma

11. Immuno-oncology Clinical Trials Market, by Sponsor Type

  • 11.1. Academic Institutions
  • 11.2. Biotechnology Companies
  • 11.3. Consortiums
  • 11.4. Pharmaceutical Companies

12. Immuno-oncology Clinical Trials Market, by Trial Type

  • 12.1. Interventional
  • 12.2. Observational

13. Immuno-oncology Clinical Trials Market, by Patient Enrollment

  • 13.1. Large Scale
  • 13.2. Medium Scale
  • 13.3. Small Scale

14. Immuno-oncology Clinical Trials Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Immuno-oncology Clinical Trials Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Immuno-oncology Clinical Trials Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Bristol-Myers Squibb Company
    • 17.3.2. Merck & Co., Inc.
    • 17.3.3. Roche Holding AG
    • 17.3.4. AstraZeneca PLC
    • 17.3.5. Novartis AG
    • 17.3.6. Pfizer Inc.
    • 17.3.7. Johnson & Johnson
    • 17.3.8. Amgen Inc.
    • 17.3.9. Sanofi S.A.
    • 17.3.10. GlaxoSmithKline plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CAR-T, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CAR-T, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CAR-T, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CAR-T, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CAR-T, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CAR-T, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TCR-T, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TCR-T, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TCR-T, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TCR-T, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TCR-T, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TCR-T, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DNA VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DNA VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON ALPHA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON ALPHA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON ALPHA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON ALPHA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON ALPHA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON ALPHA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON GAMMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON GAMMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON GAMMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON GAMMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON GAMMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON GAMMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERLEUKIN-2, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERLEUKIN-2, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERLEUKIN-2, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERLEUKIN-2, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERLEUKIN-2, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERLEUKIN-2, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MYELOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MYELOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MYELOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MYELOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MYELOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MYELOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CONSORTIUMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CONSORTIUMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CONSORTIUMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CONSORTIUMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CONSORTIUMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CONSORTIUMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LARGE SCALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LARGE SCALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LARGE SCALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LARGE SCALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LARGE SCALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LARGE SCALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MEDIUM SCALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MEDIUM SCALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MEDIUM SCALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MEDIUM SCALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MEDIUM SCALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MEDIUM SCALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SMALL SCALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SMALL SCALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SMALL SCALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SMALL SCALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SMALL SCALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SMALL SCALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 286. AMERI